Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Oral health in cancer survivors

Hani Haytham Mawardi, BDS, DMSc, DABOM, FDS RCSEd
Maha Ali Al-Mohaya, BDS, MS, DMSc, ABOM
Nathaniel S Treister, DMD, DMSc
Section Editor
Patricia A Ganz, MD
Deputy Editor
Sadhna R Vora, MD


For most cancer survivors there are no specific oral health considerations or expected late complications. However, cancer survivors prescribed bone-modifying agents, survivors of head and neck cancer, childhood cancer survivors, and patients treated on protocols involving high-dose chemotherapy and stem cell transplantation (HCT-SCT) constitute high-risk groups for oral health complications. These patients may require long-term dental follow-up well after completion of cancer therapy [1]. An overview of oral complications is shown in the table (table 1).

Since most patients are usually followed and managed by their local community dentists, communication between medical and dental providers is critical prior, during, and after cancer therapy, in order to minimize or prevent oral health complications [2,3].

This topic will review oral health considerations in cancer survivors at high risk for complications. Because head and neck cancer survivors, patients treated with hematopoietic cell transplantation who develop chronic graft-versus-host disease (GVHD), and patients taking bone modifying agents are at a significant risk for oral health complications, a detailed discussion of these patients is covered separately.

(See "Management of late complications of head and neck cancer and its treatment".)

(See "The approach to hematopoietic cell transplantation survivorship", section on 'Oral health'.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jan 12, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Epstein JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999; 21:1.
  2. Schiødt M, Hermund NU. Management of oral disease prior to radiation therapy. Support Care Cancer 2002; 10:40.
  3. Hancock PJ, Epstein JB, Sadler GR. Oral and dental management related to radiation therapy for head and neck cancer. J Can Dent Assoc 2003; 69:585.
  4. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
  5. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67:7.
  6. Pedersen LB, Clausen N, Schrøder H, et al. Microdontia and hypodontia of premolars and permanent molars in childhood cancer survivors after chemotherapy. Int J Paediatr Dent 2012; 22:239.
  7. Goho C. Chemoradiation therapy: effect on dental development. Pediatr Dent 1993; 15:6.
  8. Kaste SC, Goodman P, Leisenring W, et al. Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study. Cancer 2009; 115:5817.
  9. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330:827.
  10. Gilliam AC. Update on graft versus host disease. J Invest Dermatol 2004; 123:251.
  11. Imanguli MM, Alevizos I, Brown R, et al. Oral graft-versus-host disease. Oral Dis 2008; 14:396.
  12. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.
  13. Andrews N, Griffiths C. Dental complications of head and neck radiotherapy: Part 1. Aust Dent J 2001; 46:88.
  14. Andrews N, Griffiths C. Dental complications of head and neck radiotherapy: Part 2. Aust Dent J 2001; 46:174.
  15. Koga DH, Salvajoli JV, Alves FA. Dental extractions and radiotherapy in head and neck oncology: review of the literature. Oral Dis 2008; 14:40.
  16. McGuire DB, Johnson J, Migliorati C. Promulgation of guidelines for mucositis management: educating health care professionals and patients. Support Care Cancer 2006; 14:548.
  17. Kerawala CJ. Complications of head and neck cancer surgery - prevention and management. Oral Oncol 2010; 46:433.
  18. Kerawala CJ, Heliotos M. Prevention of complications in neck dissection. Head Neck Oncol 2009; 1:35.
  19. Denaro N, Russi EG, Adamo V, et al. Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions. Oncology 2011; 81:21.
  20. Jensen SB, Mouridsen HT, Reibel J, et al. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol 2008; 44:162.
  21. Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res 2000; 79:1874.
  22. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 1987; 66 Spec No:648.
  23. Sreebny LM. Saliva in health and disease: an appraisal and update. Int Dent J 2000; 50:140.
  24. Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010; 18:1039.
  25. Brosky ME. The role of saliva in oral health: strategies for prevention and management of xerostomia. J Support Oncol 2007; 5:215.
  26. Jellema AP, Slotman BJ, Doornaert P, et al. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69:751.
  27. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008; 26:3770.
  28. Cannon RD, Holmes AR, Mason AB, Monk BC. Oral Candida: clearance, colonization, or candidiasis? J Dent Res 1995; 74:1152.
  29. Schubert MM. Oral complications of hematopoietic cell transplantation. In: Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Wiley-Blackwell, Oxford 2009. p.1589.
  30. Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 2010; 18:985.
  31. Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1993; 76:169.
  32. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.
  33. Elad S, Zadik Y, Hewson I, et al. A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. Support Care Cancer 2010; 18:993.
  34. Arduino PG, Porter SR. Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med 2008; 37:107.
  35. Treister NS, Woo SB, O'Holleran EW, et al. Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:721.
  36. Treister NS, Cook EF Jr, Antin J, et al. Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14:110.
  37. Imanguli MM, Pavletic SZ, Guadagnini JP, et al. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101:175.
  38. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12:375.
  39. Elad S, Zeevi I, Finke J, et al. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, randomized, multicenter study. Biol Blood Marrow Transplant 2012; 18:134.
  40. Meier JK, Wolff D, Pavletic S, et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig 2011; 15:127.
  41. Albert MH, Becker B, Schuster FR, et al. Oral graft vs. host disease in children--treatment with topical tacrolimus ointment. Pediatr Transplant 2007; 11:306.
  42. Eckardt A, Starke O, Stadler M, et al. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 2004; 40:811.
  43. Bauters T, Bordon V, Van de Velde V, et al. Highly effective treatment with tacrolimus ointment in an adolescent with oral graft-versus-host disease. Pharm World Sci 2010; 32:350.
  44. Chrcanovic BR, Reher P, Sousa AA, Harris M. Osteoradionecrosis of the jaws--a current overview--part 1: Physiopathology and risk and predisposing factors. Oral Maxillofac Surg 2010; 14:3.
  45. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21:4253.
  46. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115.
  47. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527.
  48. Fusco V, Galassi C, Berruti A, et al. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol 2011; 29:e521.
  49. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 2011; 8:90.
  50. Migliorati CA, Woo SB, Hewson I, et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010; 18:1099.
  51. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaws. Compend Contin Educ Dent 2008; 29:96.
  52. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009; 35:119.
  53. Chopra S, Kamdar D, Ugur OE, et al. Factors predictive of severity of osteoradionecrosis of the mandible. Head Neck 2011; 33:1600.
  54. Cheng SJ, Lee JJ, Ting LL, et al. A clinical staging system and treatment guidelines for maxillary osteoradionecrosis in irradiated nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2006; 64:90.
  55. Pitak-Arnnop P, Sader R, Dhanuthai K, et al. Management of osteoradionecrosis of the jaws: an analysis of evidence. Eur J Surg Oncol 2008; 34:1123.
  56. Shaha AR, Cordeiro PG, Hidalgo DA, et al. Resection and immediate microvascular reconstruction in the management of osteoradionecrosis of the mandible. Head Neck 1997; 19:406.
  57. Hao SP, Chen HC, Wei FC, et al. Systematic management of osteoradionecrosis in the head and neck. Laryngoscope 1999; 109:1324.
  58. Notani K, Yamazaki Y, Kitada H, et al. Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy. Head Neck 2003; 25:181.
  59. Dijkstra PU, Kalk WW, Roodenburg JL. Trismus in head and neck oncology: a systematic review. Oral Oncol 2004; 40:879.
  60. Bensadoun RJ, Riesenbeck D, Lockhart PB, et al. A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer 2010; 18:1033.
  61. Dijkstra PU, Sterken MW, Pater R, et al. Exercise therapy for trismus in head and neck cancer. Oral Oncol 2007; 43:389.
  62. Grandi G, Silva ML, Streit C, Wagner JC. A mobilization regimen to prevent mandibular hypomobility in irradiated patients: an analysis and comparison of two techniques. Med Oral Patol Oral Cir Bucal 2007; 12:E105.
  63. Melchers LJ, Van Weert E, Beurskens CH, et al. Exercise adherence in patients with trismus due to head and neck oncology: a qualitative study into the use of the Therabite. Int J Oral Maxillofac Surg 2009; 38:947.
  64. Stubblefield MD, Manfield L, Riedel ER. A preliminary report on the efficacy of a dynamic jaw opening device (dynasplint trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. Arch Phys Med Rehabil 2010; 91:1278.
  65. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321:784.
  66. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87:3633.
  67. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol 2008; 44:743.
  68. Zachariades N. Neoplasms metastatic to the mouth, jaws and surrounding tissues. J Craniomaxillofac Surg 1989; 17:283.
  69. Pires FR, de Almeida OP, de Araújo VC, Kowalski LP. Prognostic factors in head and neck mucoepidermoid carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130:174.
  70. Rodan GA. The development and function of the skeleton and bone metastases. Cancer 2003; 97:726.
  71. Castellarin P, Stevenson K, Biasotto M, et al. Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18:1573.